Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Regorafenib (Stivarga, BAY73- 4506) Clear all
Terminated Phase 1Phase 2 Interventional Results available

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

NCT05731947
View directory record Official record
Conditions
Colorectal Cancer, Solid Tumors
Interventions
Revumenib, Chemotherapy
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

NCT01187615
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

NCT05064059
View directory record Official record
Conditions
Colorectal Cancer
Interventions
favezelimab/pembrolizumab, regorafenib, TAS-102
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

NCT04701476
View directory record Official record
Conditions
Colorectal Cancer; Lung Cancer
Interventions
TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

NCT02383433
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Regorafenib, Gemcitabine Hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 8, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

NCT03465722
View directory record Official record
Conditions
GIST
Interventions
avapritinib, regorafenib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

NCT02115542
View directory record Official record
Conditions
Cancer of the Bile Duct
Interventions
Regorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

NCT01002378
View directory record Official record
Conditions
Dietary Fats, Pharmacokinetics
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 8, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

NCT06887218
View directory record Official record
Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab, Trifluridine-tipiracil
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

NCT06087263
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

NCT01339104
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Aurora, Colorado • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 8, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

NCT02587650
View directory record Official record
Conditions
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive, NRAS wt Allele, NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive, RET Fusion Positive, ROS1 Fusion Positive, Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Capmatinib, Ceritinib, Entrectinib, Laboratory Biomarker Analysis, Regorafenib
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

NCT05672316
View directory record Official record
Conditions
Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Regorafenib
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

NCT01973868
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Cetuximab (ERBITUX)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

NCT01271712
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo, Best supportive care
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Evanston, Illinois • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 8, 2026, 5:47 PM EDT
Withdrawn Phase 2 Interventional

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

NCT02287727
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer
Interventions
Laboratory Biomarker Analysis, Regorafenib
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
3
States / cities
Buffalo, New York • Rocherster, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Metastatic Colorectal Cancer

NCT02466009
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
70 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Rochester, Minnesota • Rochester, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154
View directory record Official record
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 8, 2026, 5:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

NCT05194293
View directory record Official record
Conditions
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Interventions
Durvalumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

NCT02259725
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
regorafenib, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 8, 2026, 5:47 PM EDT
Completed No phase listed Observational

An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe

NCT05551039
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Retrospective patient chart review
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

NCT01318265
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 8, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

NCT03712943
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer
Interventions
Regorafenib, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 8, 2026, 5:47 PM EDT